Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen

We established a split nanoluciferase complementation assay to rapidly screen for inhibitors that interfere with binding of the receptor binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein with its target receptor, angiotensin-converting enzyme...

Descripción completa

Detalles Bibliográficos
Autores principales: Taha, Zaid, Arulanandam, Rozanne, Maznyi, Glib, Godbout, Elena, Carter-Timofte, Madalina E., Kurmasheva, Naziia, Reinert, Line S., Chen, Andrew, Crupi, Mathieu J.F., Boulton, Stephen, Laroche, Geneviève, Phan, Alexandra, Rezaei, Reza, Alluqmani, Nouf, Jirovec, Anna, Acal, Alexandra, Brown, Emily E.F., Singaravelu, Ragunath, Petryk, Julia, Idorn, Manja, Potts, Kyle G., Todesco, Hayley, John, Cini, Mahoney, Douglas J., Ilkow, Carolina S., Giguère, Patrick, Alain, Tommy, Côté, Marceline, Paludan, Søren R., Olagnier, David, Bell, John C., Azad, Taha, Diallo, Jean-Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075979/
https://www.ncbi.nlm.nih.gov/pubmed/35526097
http://dx.doi.org/10.1016/j.ymthe.2022.04.025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075979/
https://www.ncbi.nlm.nih.gov/pubmed/35526097
http://dx.doi.org/10.1016/j.ymthe.2022.04.025

Ejemplares similares